Lowenstein has advised Matinas in the sale of Matinas BioPharma Nanotechnologies to Azurity Pharmaceuticals. Matinas BioPharma has entered into a definitive stock purchase agreement to sell...
Azurity Pharmaceuticals to Acquire Matinas BioPharma Nanotechnologies
Matinas BioPharma and GH Power Announce Business Combination to Create NYSE-listed Clean Energy and Critical Minerals Company
Lowenstein Sandler LLP has represented Matinas BioPharma Holdings, Inc. in its business combination agreement with GH Power, Inc. Matinas BioPharma Holdings, Inc., a biopharmaceutical company listed...
First Wave BioPharma’s Acquisition of ImmunogenX
Lowenstein represented First Wave BioPharma, Inc. in the transaction. First Wave BioPharma, Inc. (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic...
DarioHealth’s Acquisition of Twill
Lowenstein Sandler represented Twill, Inc. in the transaction. DarioHealth Corp. (NASDAQ: DRIO) executed the acquisition of Twill, Inc., a leader in digital-led care. The combination enables Dario...
Corbus Pharmaceuticals’ $94.5 Million Shares Public Offering
Lowenstein Sandler represented Corbus Pharmaceuticals Holdings, Inc. in the transaction. Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a precision oncology company with a diversified portfolio, announced the...
Coya Therapeutics’ $26.5 Million Private Placement
Lowenstein Sandler represented Coya Therapeutics in the transaction. Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotechnology company, announced the sale of $26.5 million worth of stock in a...
Coya Therapeutics’ Development-and-License Deal with Dr. Reddy’s Laboratories
Lowenstein Sandler represented Coya Therapeutics in the transaction. Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotechnology company, announced a development-and-license deal with Dr. Reddy’s Laboratories for its...
First Wave Biopharma’s License Agreement with Sanofi for Capeserod
Lowenstein Sandler represented First Wave BioPharma, Inc. in the transaction. First Wave BioPharma, Inc., (NASDAQ:FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic...
Tonix Pharmaceuticals’ $25 Million Acquisition of FDA-Approved Products from Upsher-Smith Laboratories
Lowenstein represented Tonix Pharmaceuticals Holding Corp. in the transaction. Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage biopharmaceutical company, announced its $25 million acquisition of two...
Tonix Pharmaceuticals’ Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio
Lowenstein represented Tonix Pharmaceuticals Holding Corp. in the transaction. Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) signed an agreement to acquire assets of Healion Bio, Inc., including its...
Coya Therapeutics’ $15.25 Million Initial Public Offering
Lowenstein Sandler represented Coya Therapeutics in the transaction. Coya Therapeutics, Inc. (Nasdaq: COYA), a clinical-stage biotechnology company developing proprietary therapies to enhance the function of regulatory...
LTS Lohmann Therapy Systems’ Acquisition of Tapemark
Lowenstein Sandler represented LTS Lohmann Therapy Systems, Corp. in the transaction. LTS Lohmann Therapy Systems, Corp. (“LTS”) executed its acquisition of Tapemark Inc. (“Tapemark”) located in...